Amarin Corporation Plc (AMRN) 2.09 $AMRN
Amarin to Host Second Quarter 2015 Earnings Conference Call and Webcast Live on Thursday, August 6, 2015
ACCESSWIRE - Wed Aug 05, 3:16PM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / August 5, 2015 / Amarin Corporation plc (NASDAQ: AMRN) will host a conference call and live webcast to discuss the results of the second quarter 2015, to be held Thursday, August 6, 2015 at 4:30 PM Eastern Time.
AMRN: 2.09 (-0.11)
Amarin Announces Upcoming Presentations of Two Eicosapentaenoic Acid (EPA) Studies at the American Society for Preventive Cardiology (ASPC) Annual Cardiovascular Disease Prevention Conference and the Kern Lipid Conference
Marketwired - Fri Jul 31, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN) today announced the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA plus DHA combination product to EPA-only Vascepa® (icosapent ethyl) as well as a sub-analysis of the ANCHOR clinical trial, at two key cardiovascular meetings: the American Society for Preventive Cardiology Annual Cardiovascular Disease Prevention Conference (July 31-August 2, Boca Raton, FL) and the Kern Lipid Conference (August 3-5, Vail, CO), respectively.
AMRN: 2.09 (-0.11)
Amarin Announces Upcoming Presentations of Two Eicosapentaenoic Acid (EPA) Studies at the American Society for Preventive Cardiology (ASPC) Annual Cardiovascular Disease Prevention Conference and the Kern Lipid Conference
Marketwire Canada - Fri Jul 31, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN) today announced the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA plus DHA combination product to EPA-only VascepaA® (icosapent ethyl) as well as a sub-analysis of the ANCHOR clinical trial, at two key cardiovascular meetings: the American Society for Preventive Cardiology Annual Cardiovascular Disease Prevention Conference (July 31-August 2, Boca Raton, FL) and the Kern Lipid Conference (August 3-5, Vail, CO), respectively.
AMRN: 2.09 (-0.11)
Market Updates on Drug Manufacturers - Other Equities -- Isis Pharma, Endo Intl., Amarin, United Therapeutics, and POZEN
PR Newswire - Thu Jul 30, 8:10AM CDT
36Equity Research Institute has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Endo International PLC (NASDAQ: ENDP), Amarin Corporation PLC (NASDAQ: AMRN), United Therapeutics Corporation (NASDAQ: UTHR), and POZEN Inc. (NASDAQ: POZN). Free research report on Isis Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ISIS On Wednesday, July 29, 2015, the NASDAQ Composite ended at 5,111.73, up 0.44%, the Dow Jones Industrial Average advanced 0.69%, to finish the day at 17,751.39, and the S&P 500 closed at 2,108.57, up 0.73%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
ENDP: 85.85 (+0.74), ISIS: 54.52 (-0.78), UTHR: 166.55 (+2.82), AMRN: 2.09 (-0.11), POZN: 11.70 (-0.09)
Amarin to Report Second Quarter 2015 Results and Host Conference Call on August 6, 2015
Marketwired - Thu Jul 30, 6:01AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2015 financial results and provide an operational update on Thursday, August 6, at 4:30 p.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.
AMRN: 2.09 (-0.11)
3 Things You Should Know About Amarin Plc
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 11, 9:03AM CDT
Amarin has faced its fair share of troubles commercializing its triglycerides-lowering drug Vascepa, but Amarin remains hopeful that Vascepa will be able to make good on its previously high expectations. Here are three things that investors need to...
AMRN: 2.09 (-0.11)
5 Stocks Ready for Breakouts -- Must-See Charts
at The Street - Fri Jul 10, 8:35AM CDT
These stock charts look ready to break out and trade higher from current levels.
VSTM: 7.12 (unch), KITE: 76.50 (+2.96), GKOS: 32.30 (+0.04), AMRN: 2.09 (-0.11), CTCT: 25.50 (+0.14)
3 Stocks Under $10 Making Big Moves
at The Street - Tue Jun 16, 12:49PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
MELA: 1.11 (-0.03), AMRN: 2.09 (-0.11), NSPR: 0.25 (-0.03)
3 Biotech Stocks That I Won't Buy
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 13, 7:04AM CDT
Source: Flickr user sboneham . I tend to be more of a growth investor than a value investor, and as a result I often lean toward buying shares of biotechs that are working on intriguing late-stage medicines. However, not all biotech stocks are...
AMRN: 2.09 (-0.11), SNY: 54.71 (+1.22), MNKD: 4.19 (+0.04), ARNA: 4.03 (-0.02)
New In Vitro Eicosapentaenoic Acid Study Data to Be Presented at the National Lipid Association Scientific Sessions in Chicago
Marketwired - Thu Jun 11, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN) announced today the presentation of findings from a new in vitro study at the National Lipid Association Scientific Sessions being held June 11-14 in Chicago. The study of the inhibitory effect of eicosapentaenoic acid (EPA) on the formation of cholesterol crystalline domains in model biological membranes subjected to high cholesterol levels (to simulate atherosclerotic-like conditions) indicated a level of reduction with EPA that was not reproduced with other triglyceride-lowering agents tested. The poster, titled "Eicosapentaenoic Acid (EPA), But Not Other TG-Lowering Agents, Reduces Cholesterol Domain Levels in Atherosclerotic-Like Model Membranes," will be presented at the author Q&A session scheduled for June 13, 2015 from 11:20 a.m.-12:20 p.m. CDT.
AMRN: 2.09 (-0.11)
New In Vitro Eicosapentaenoic Acid Study Data Presented June 6 at the American Diabetes Association Scientific Sessions in Boston
Marketwired - Mon Jun 08, 6:01AM CDT
Amarin Corporation plc (NASDAQ: AMRN) announced today the presentation of findings from a new in vitro study at a peer-reviewed poster session at the American Diabetes Association Scientific Sessions in Boston, Massachusetts.
AMRN: 2.09 (-0.11)
Amarin Corporation PLC Shares Lifted Off in May -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 05, 7:02AM CDT
What: Shares of Amarin , a small-cap biopharmaceutical company focused on developing drugs designed to treat cardiovascular diseases, lifted off in May and rose by 20% based on data from S&P Capital IQ , after announcing a positive judgment...
AMRN: 2.09 (-0.11)
Matinas and Amarin's Destinies are Linked as MAT9001 Outshines Vascepa
ACCESSWIRE - Wed Jun 03, 2:42PM CDT
CORAL GABLES, FL / ACCESSWIRE / June 3, 2015 / It was April 2011 and Amarin (NASDAQ: AMRN) shareholders were flying high. As data came in for the company's pivotal phase 3 trial for Vascepa, an omega-3 fatty acid drug trialed to reduce very high triglycerides in the blood, shares went from $8.75 to a high of $19.50 just over a month later. But as excitement wore off, shares had collapsed down to pre-data-release levels by December.
AZN: 34.54 (+0.20), AMRN: 2.09 (-0.11), GSK: 44.17 (+0.72)
Matinas MAT9001 Beats Vascepa In Head-To-Head Trial
Jason Napodano, CFA - at Seeking Alpha - Mon Jun 01, 1:28PM CDT
AMRN: 2.09 (-0.11)
Amarin: 5-Year Vascepa NCE Exclusivity A Boon To Its Post REDUCE-IT Potential
Elephant Analytics - at Seeking Alpha - Sat May 30, 7:08AM CDT
AMRN: 2.09 (-0.11)
Major Court Victory De-Risks Amarin Corp.
Clinically Sound Investor - at Seeking Alpha - Fri May 29, 11:08AM CDT
AMRN: 2.09 (-0.11)
Investors look to Lighten Up on Shares of Amarin, Shares Down 6.0% (AMRN)
Comtex SmarTrend(R) - Fri May 29, 10:17AM CDT
Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 6.0% to $2.18 on 1.6x average daily volume. Thus far today, Amarin has traded 3.0 million shares, vs. average volume of 1.9 million shares per day. The stock has underperformed the Dow (-6.0% to the Dow's -0.7%) and underperformed the S&P 500 (-6.0% to the S&P's -0.6%) during today's trading.
AMRN: 2.09 (-0.11)
Amarin to Host Second Quarter 2015 Earnings Conference Call and Webcast Live on Thursday, August 6, 2015
ACCESSWIRE - Wed Aug 05, 3:16PM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / August 5, 2015 / Amarin Corporation plc (NASDAQ: AMRN) will host a conference call and live webcast to discuss the results of the second quarter 2015, to be held Thursday, August 6, 2015 at 4:30 PM Eastern Time.
AMRN: 2.09 (-0.11)
Amarin Announces Upcoming Presentations of Two Eicosapentaenoic Acid (EPA) Studies at the American Society for Preventive Cardiology (ASPC) Annual Cardiovascular Disease Prevention Conference and the Kern Lipid Conference
Marketwired - Fri Jul 31, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN) today announced the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA plus DHA combination product to EPA-only Vascepa® (icosapent ethyl) as well as a sub-analysis of the ANCHOR clinical trial, at two key cardiovascular meetings: the American Society for Preventive Cardiology Annual Cardiovascular Disease Prevention Conference (July 31-August 2, Boca Raton, FL) and the Kern Lipid Conference (August 3-5, Vail, CO), respectively.
AMRN: 2.09 (-0.11)
Amarin Announces Upcoming Presentations of Two Eicosapentaenoic Acid (EPA) Studies at the American Society for Preventive Cardiology (ASPC) Annual Cardiovascular Disease Prevention Conference and the Kern Lipid Conference
Marketwire Canada - Fri Jul 31, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN) today announced the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA plus DHA combination product to EPA-only VascepaA® (icosapent ethyl) as well as a sub-analysis of the ANCHOR clinical trial, at two key cardiovascular meetings: the American Society for Preventive Cardiology Annual Cardiovascular Disease Prevention Conference (July 31-August 2, Boca Raton, FL) and the Kern Lipid Conference (August 3-5, Vail, CO), respectively.
AMRN: 2.09 (-0.11)
Market Updates on Drug Manufacturers - Other Equities -- Isis Pharma, Endo Intl., Amarin, United Therapeutics, and POZEN
PR Newswire - Thu Jul 30, 8:10AM CDT
36Equity Research Institute has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Endo International PLC (NASDAQ: ENDP), Amarin Corporation PLC (NASDAQ: AMRN), United Therapeutics Corporation (NASDAQ: UTHR), and POZEN Inc. (NASDAQ: POZN). Free research report on Isis Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ISIS On Wednesday, July 29, 2015, the NASDAQ Composite ended at 5,111.73, up 0.44%, the Dow Jones Industrial Average advanced 0.69%, to finish the day at 17,751.39, and the S&P 500 closed at 2,108.57, up 0.73%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
ENDP: 85.85 (+0.74), ISIS: 54.52 (-0.78), UTHR: 166.55 (+2.82), AMRN: 2.09 (-0.11), POZN: 11.70 (-0.09)
Amarin to Report Second Quarter 2015 Results and Host Conference Call on August 6, 2015
Marketwired - Thu Jul 30, 6:01AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2015 financial results and provide an operational update on Thursday, August 6, at 4:30 p.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.
AMRN: 2.09 (-0.11)
3 Things You Should Know About Amarin Plc
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 11, 9:03AM CDT
Amarin has faced its fair share of troubles commercializing its triglycerides-lowering drug Vascepa, but Amarin remains hopeful that Vascepa will be able to make good on its previously high expectations. Here are three things that investors need to...
AMRN: 2.09 (-0.11)
5 Stocks Ready for Breakouts -- Must-See Charts
at The Street - Fri Jul 10, 8:35AM CDT
These stock charts look ready to break out and trade higher from current levels.
VSTM: 7.12 (unch), KITE: 76.50 (+2.96), GKOS: 32.30 (+0.04), AMRN: 2.09 (-0.11), CTCT: 25.50 (+0.14)
3 Stocks Under $10 Making Big Moves
at The Street - Tue Jun 16, 12:49PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
MELA: 1.11 (-0.03), AMRN: 2.09 (-0.11), NSPR: 0.25 (-0.03)
3 Biotech Stocks That I Won't Buy
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 13, 7:04AM CDT
Source: Flickr user sboneham . I tend to be more of a growth investor than a value investor, and as a result I often lean toward buying shares of biotechs that are working on intriguing late-stage medicines. However, not all biotech stocks are...
AMRN: 2.09 (-0.11), SNY: 54.71 (+1.22), MNKD: 4.19 (+0.04), ARNA: 4.03 (-0.02)
New In Vitro Eicosapentaenoic Acid Study Data to Be Presented at the National Lipid Association Scientific Sessions in Chicago
Marketwired - Thu Jun 11, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN) announced today the presentation of findings from a new in vitro study at the National Lipid Association Scientific Sessions being held June 11-14 in Chicago. The study of the inhibitory effect of eicosapentaenoic acid (EPA) on the formation of cholesterol crystalline domains in model biological membranes subjected to high cholesterol levels (to simulate atherosclerotic-like conditions) indicated a level of reduction with EPA that was not reproduced with other triglyceride-lowering agents tested. The poster, titled "Eicosapentaenoic Acid (EPA), But Not Other TG-Lowering Agents, Reduces Cholesterol Domain Levels in Atherosclerotic-Like Model Membranes," will be presented at the author Q&A session scheduled for June 13, 2015 from 11:20 a.m.-12:20 p.m. CDT.
AMRN: 2.09 (-0.11)
New In Vitro Eicosapentaenoic Acid Study Data Presented June 6 at the American Diabetes Association Scientific Sessions in Boston
Marketwired - Mon Jun 08, 6:01AM CDT
Amarin Corporation plc (NASDAQ: AMRN) announced today the presentation of findings from a new in vitro study at a peer-reviewed poster session at the American Diabetes Association Scientific Sessions in Boston, Massachusetts.
AMRN: 2.09 (-0.11)
Amarin Corporation PLC Shares Lifted Off in May -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 05, 7:02AM CDT
What: Shares of Amarin , a small-cap biopharmaceutical company focused on developing drugs designed to treat cardiovascular diseases, lifted off in May and rose by 20% based on data from S&P Capital IQ , after announcing a positive judgment...
AMRN: 2.09 (-0.11)
Matinas and Amarin's Destinies are Linked as MAT9001 Outshines Vascepa
ACCESSWIRE - Wed Jun 03, 2:42PM CDT
CORAL GABLES, FL / ACCESSWIRE / June 3, 2015 / It was April 2011 and Amarin (NASDAQ: AMRN) shareholders were flying high. As data came in for the company's pivotal phase 3 trial for Vascepa, an omega-3 fatty acid drug trialed to reduce very high triglycerides in the blood, shares went from $8.75 to a high of $19.50 just over a month later. But as excitement wore off, shares had collapsed down to pre-data-release levels by December.
AZN: 34.54 (+0.20), AMRN: 2.09 (-0.11), GSK: 44.17 (+0.72)
Matinas MAT9001 Beats Vascepa In Head-To-Head Trial
Jason Napodano, CFA - at Seeking Alpha - Mon Jun 01, 1:28PM CDT
AMRN: 2.09 (-0.11)
Amarin: 5-Year Vascepa NCE Exclusivity A Boon To Its Post REDUCE-IT Potential
Elephant Analytics - at Seeking Alpha - Sat May 30, 7:08AM CDT
AMRN: 2.09 (-0.11)
Major Court Victory De-Risks Amarin Corp.
Clinically Sound Investor - at Seeking Alpha - Fri May 29, 11:08AM CDT
AMRN: 2.09 (-0.11)
Investors look to Lighten Up on Shares of Amarin, Shares Down 6.0% (AMRN)
Comtex SmarTrend(R) - Fri May 29, 10:17AM CDT
Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 6.0% to $2.18 on 1.6x average daily volume. Thus far today, Amarin has traded 3.0 million shares, vs. average volume of 1.9 million shares per day. The stock has underperformed the Dow (-6.0% to the Dow's -0.7%) and underperformed the S&P 500 (-6.0% to the S&P's -0.6%) during today's trading.
AMRN: 2.09 (-0.11)
